Cosmos Health Inc. manufactures and distributes branded pharmaceutical products, nutraceuticals, medical devices, and consumer health items across multiple markets in Europe and the Middle East. The company operates primarily through two product categories: branded pharmaceuticals and over-the-counter health products. Its pharmaceutical portfolio includes generic medications such as pravastatin, omeprazole, clopidogrel, atorvastatin, and donepezil, marketed under proprietary brand names. The company also produces food supplements, cosmetics, biocides, and antiseptic soaps under the C-Sept and C-Scrub brands, alongside baby food products under the Bio-bebe brand.
Cosmos Health serves wholesalers and retail healthcare providers across Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company operates with approximately 149 full-time employees and maintains headquarters in Chicago, Illinois, though its primary market presence is in Europe and the Middle East. The business model centers on distributing branded versions of established pharmaceutical active ingredients alongside proprietary nutraceutical and consumer health products to regional healthcare distribution networks and retailers.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.17 | $-1.17 | +45.6% | |
| 2023 | $-2.15 | $-2.15 | +93.5% | |
| 2022 | $-33.16 | $-33.16 | -3390.5% | |
| 2021 | $-0.95 | $-0.95 | -1683.3% | |
| 2020 | $0.06 | $0.06 | +124.0% | |
| 2019 | $-0.25 | $-0.25 | +63.2% | |
| 2018 | $-0.68 | $-0.68 | -100.0% | |
| 2017 | $677206.00 | — | — | |
| 2016 | $0.00 | $0.00 | +100.0% | |
| 2015 | $-0.05 | $-0.05 | -200.0% | |
| 2014 | $0.05 | $0.05 | — | |
| 2013 | $0.00 | $0.00 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-04-15 | 0001477932-25-002759 | SEC ↗ |
| 2023-12-31 | 2024-08-05 | 0001477932-24-004545 | SEC ↗ |
| 2022-12-31 | 2023-04-12 | 0001477932-23-002443 | SEC ↗ |
| 2021-12-31 | 2022-04-15 | 0001477932-22-002405 | SEC ↗ |
| 2020-12-31 | 2021-04-15 | 0001477932-21-002377 | SEC ↗ |
| 2019-12-31 | 2020-04-14 | 0001477932-20-001964 | SEC ↗ |
| 2018-12-31 | 2019-04-16 | 0001477932-19-001806 | SEC ↗ |
| 2017-12-31 | 2018-04-17 | 0001477932-18-001899 | SEC ↗ |
| 2016-12-31 | 2017-04-17 | 0001477932-17-001760 | SEC ↗ |
| 2015-12-31 | 2016-04-20 | 0001477932-16-009868 | SEC ↗ |
| 2014-12-31 | 2015-04-15 | 0001477932-15-002471 | SEC ↗ |
| 2013-12-31 | 2014-04-11 | 0001477932-14-001658 | SEC ↗ |
| 2013-07-31 | 2013-09-13 | 0001477932-13-004207 | SEC ↗ |
| 2012-07-31 | 2012-10-26 | 0001144204-12-057931 | SEC ↗ |
| 2011-07-31 | 2011-11-02 | 0001144204-11-060766 | SEC ↗ |
| 2010-07-31 | 2010-11-15 | 0001144204-10-060643 | SEC ↗ |